Back to top
more

Organon & Co. (OGN)

(Real Time Quote from BATS)

$8.45 USD

8.45
3,012,154

+0.05 (0.60%)

Updated Aug 6, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss

by Zacks Equity Research

Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.

Zacks Equity Research

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Shaun Pruitt headshot

Don't Overlook These Low-Risk High-Dividend Yielding Stocks

by Shaun Pruitt

Now looks like a good time to buy these highly ranked stocks with earnings estimate revisions likely to keep ticking up after their favorable Q4 results which makes their high dividend yields and low beta ratios more attractive.

Zacks Equity Research

The Zacks Analyst Blog Highlights Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon

by Zacks Equity Research

Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon are included in this Analyst Blog.

Nalak Das headshot

Top 5 Low-Beta High-Yielding Stocks to Shield Your Portfolio

by Nalak Das

We have narrowed our search to five low-beta (beta >0 <1) stocks with a solid dividend yield. These are: BAH, AXS, OGN, TSN, FFIN.

Zacks Equity Research

Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DES

Zacks Equity Research

Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DES

Zacks Equity Research

Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) Q3 Earnings Match Estimates

by Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Organon (OGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sotera Health Company (SHC) Tops Q2 Earnings Estimates

by Zacks Equity Research

Sotera Health Company (SHC) delivered earnings and revenue surprises of 16.67% and 2.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Organon (OGN) Lags Q1 Earnings Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of -8.47% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Organon (OGN) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of -4.71% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Organon (OGN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: InnovAge Holding Corp. (INNV) Q1 Earnings Expected to Decline

by Zacks Equity Research

InnovAge Holding Corp. (INNV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EZM